VANDA PHARMACEUTICAL INITIATED WITH 'BUY'

Analysts at Banc of America Securities initiate coverage of Vanda Pharmaceutical Inc (ticker: VNDA) with a "buy" rating. The target price is set to $14. Newratings (http://www.newratings.com/analyst_news/article_1281879.html)